Literatur zu Giordano/Wenz: Strahlentherapie kompakt, 3. Auflage
Kap. 1
Bartelink H, Maingon P, Poortmans P et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015;16(1): 47–56.
Coles CE, Griffin CL, Kirby AM et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, noninferiority trial. Lancet. 2017;390(10099): 1048–60.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), McGale P, Taylor C et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935): 2127–35.
Fyles AW, McCready DR, Manchul LA et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004;351(10): 963–70.
Haviland JS, Owen JR, Dewar JA et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086–94.
Hughes KS, Schnaper LA, Bellon JR et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term followup of CALGB 9343. J Clin Oncol. 2013;31(19): 2382–87.
Strnad V, Ott OJ, Hildebrandt G et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet. 2016;387(10015): 229–38.
Vaidya JS, Wenz F, Bulsara M et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control
and overall survival from the TARGIT-A randomised trial. Lancet. 2014;383(9917): 603–13.
Veronesi U, Marubini E, Mariani L et al. Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol. 2001;12(7): 997–1003.
Veronesi U, Orecchia R, Maisonneuve P et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. 2013;14(13):1269–77.
Whelan TJ, Pignol JP, Levine MN et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 362(6):513–20.
Kap. 2
Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we need to know and the path forward. Nat Rev Cancer 2017;17, 725–37
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 2018;553, 446–54.
Yap TTA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer 2017;17475–88.
Kap. 3
Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003 Jan 1;21(1):92–8.
Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998 Apr;16(4):1310–7.
Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014 Sep 20;32(27):2940–50.
Budach V, Stuschke M, Budach W, Baumann M, Geismar D, Grabenbauer G, Lammert I, Jahnke K, Stueben G, Herrmann T, Bamberg M, Wust P, Hinkelbein W, Wernecke KD. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol. 2005 Feb 20;23(6):1125–35.
Baujat B, Bourhis J, Blanchard P, Overgaard J, Ang KK, Saunders M, Le Maître A, Bernier J, Horiot JC, Maillard E, Pajak TF, Poulsen MG, Bourredjem A, O'Sullivan B, Dobrowsky W, Andrzej H, Skladowski K, Hay JH, Pinto LH, Fu KK, Fallai C, Sylvester R, Pignon JP; MARCH Collaborative Group. Hyperfractionated or accelerated radiotherapy for head and neck cancer. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD002026. doi: 10.1002/14651858.CD002026.
Beitler JJ, Zhang Q, Fu KK, Trotti A, Spencer SA, Jones CU, Garden AS, Shenouda G, Harris J, Ang KK. Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):13–20. doi: 10.1016/j. ijrobp.2013.12.027. Epub 2014 Mar 7.
Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lefèbvre JL. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005 Oct;27(10):843–50.
Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M; European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004 May 6;350(19):1945–52.
Blanchard P, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 100 randomized trials and 19,248 patients, on behalf of MACH-NC group. Annals of Oncology 27 (Supplement 6): vi328–vi350, 2016
Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, Chan AT, Huang PY, Benhamou E, Zhu G, Chua DT, Chen Y, Mai HQ, Kwong DL, Cheah SL, Moon J, Tung Y, Chi KH, Fountzilas G, Zhang L, Hui EP, Lu TX, Bourhis J, Pignon JP; MAC-NPC Collaborative Group. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015 Jun;16(6):645–55.
Boero IJ, Paravati AJ, Xu B, Cohen EE, Mell LK, Le QT, Murphy JD. Importance of Radiation Oncologist Experience Among Patients With Head-and-Neck Cancer
Treated With Intensity-Modulated Radiation Therapy. J Clin Oncol. 2016 Mar 1;34(7):684–90. doi: 10.1200/ JCO.2015.63.9898. Epub 2016 Jan 4.
Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010 Jan;11(1):21–8.
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006 Feb 9;354(6):567–78.
Bourhis J, Sire C, Graff P, Grégoire V, Maingon P, Calais G, Gery B, Martin L, Alfonsi M, Desprez P, Pignon T, Bardet E, Rives M, Geoffrois L, Daly-Schveitzer N, Sen S, Tuchais C, Dupuis O, Guerif S, Lapeyre M, Favrel V, Hamoir M, Lusinchi A, Temam S, Pinna A, Tao YG, Blanchard P, Aupérin A. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol. 2012 Feb;13(2):145–53.
Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, Horiot JC, Le Maître A, Pajak TF, Poulsen MG, O'Sullivan B, Dobrowsky W, Hliniak A, Skladowski K, Hay JH, Pinto LH, Fallai C, Fu KK, Sylvester R, Pignon JP; MetaAnalysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006 Sep 2;368(9538):843–54.
Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F, Zhang J, Russell L, Oster W, Sauer R. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000 Oct 1;18(19):3339–45.
Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, George SL, Huang AT, Prosnitz LR. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998 Jun 18;338(25):1798–804.
Budach W, Bölke E, Kammers K, Gerber PA, Orth K, Gripp S, Matuschek C. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radiochemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials. Radiother Oncol. 2016 Feb;118(2):238–43.
Cohen EE, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014 Sep 1;32(25):2735–43.
Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Lustig
R, Ensley JF, Thorstad W, Schultz CJ, Yom SS, Ang KK. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1198–205.
Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK; Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004 May 6;350(19):1937–44.
Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Calais G. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advancedstage oropharynx carcinoma. J Clin Oncol. 2004 Jan 1;22(1):69–76.
Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013 Mar 1;31(7):845–52.
Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003 Nov 27;349(22):2091–8.
Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7–16.
Ghi MG, et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. Ann Oncol. 2017 Sep 1;28(9):2206–12. doi: 10.1093/annonc/ mdx299.
GORTEC/Calais G, et al., Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999 Dec 15;91(24):2081–6.
Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013 Mar;14(3):257–64.
Huguenin P, Beer KT, Allal A, Rufibach K, Friedli C, Davis JB, Pestalozzi B, Schmid S, Thöni A, Ozsahin M, Bernier J, Töpfer M, Kann R, Meier UR, Thum P, Bieri S, Notter M, Lombriser N, Glanzmann C. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol. 2004 Dec 1;22(23):4665–73.
Janoray G, Pointreau Y, Garaud P, Chapet S, Alfonsi M, Sire C, Jadaud E, Calais G. Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation. J Natl Cancer Inst. 2015 Dec 16;108(4).
Kam MK, Leung SF, Zee B, Chau RM, Suen JJ, Mo F, Lai M, Ho R, Cheung KY, Yu BK, Chiu SK, Choi PH, Teo PM, Kwan WH, Chan AT. Prospective randomized study of intensitymodulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007 Nov 1;25(31):4873–9.
Lacas B, Bourhis J, Overgaard J, Zhang Q, Grégoire V, Nankivell M, Zackrisson B, Szutkowski Z, Suwiński R, Poulsen M, O'Sullivan B, Corvò R, Laskar SG, Fallai C, Yamazaki H, Dobrowsky W, Cho KH, Beadle B, Langendijk JA, Viegas CMP, Hay J, Lotayef M, Parmar MKB, Aupérin A, van Herpen C, Maingon P, Trotti AM, Grau C, Pignon JP, Blanchard P; MARCH Collaborative Group. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017 Sep;18(9):1221–37.
Lee NY, Zhang Q, Pfister DG, Kim J, Garden AS, Mechalakos J, Hu K, Le QT, Colevas AD, Glisson BS, Chan AT, Ang KK. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol. 2012 Feb;13(2):172–80.
Lefebvre JL, Andry G, Chevalier D, Luboinski B, Collette L, Traissac L, de Raucourt D, Langendijk JA; EORTC Head and Neck Cancer Group. Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. Ann Oncol. 2012 Oct;23(10):2708–14
Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996 Jul 3;88(13):890–9.
Lindberg R. Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer. 1972 Jun;29(6):1446–9.
Mortensen HR, Overgaard J, Specht L, Overgaard M, Johansen J, Evensen JF, Andersen LJ, Andersen E, Grau C. Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer. Radiother Oncol. 2012 Apr;103(1):69–75.
Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, Kim H, Silverman C, Raben A, Galloway TJ, Fortin A, Gore E, Westra WH, Chung CH, Jordan RC,
Gillison ML, List M, Le QT. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol. 2014 Dec 1;32(34):3858–66.
Noronha V, Joshi A, Patil VM, Agarwal J, Ghosh-Laskar S, Budrukkar A, Murthy V, Gupta T, D'Cruz AK, Banavali S, Pai PS, Chaturvedi P, Chaukar D, Pande N, Chandrasekharan A, Talreja V, Vallathol DH, Mathrudev V, Manjrekar A, Maske K, Bhelekar AS, Nawale K, Kannan S, Gota V, Bhattacharjee A, Kane S, Juvekar SL, Prabhash K. Once-aWeek Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial. J Clin Oncol. 2018 Apr 10;36(11):1064–72. Nutting, Lancet Oncol 2011
Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, Bentzen J, Bastholt L, Hansen O, Johansen J, Andersen L, Evensen JF. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 2003 Sep 20;362(9388):933–40. Peng, Radiother Oncol, 2012: Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, Faivre S, Guerrif S, Alfonsi M, Calais G. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009 Apr 1;101(7):498–506.
Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI; TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007 Oct 25;357(17):1705–15.
Ribassin-Majed L, Marguet S, Lee AWM, Ng WT, Ma J, Chan ATC, Huang PY, Zhu G, Chua DTT, Chen Y, Mai HQ, Kwong DLW, Cheah SL, Moon J, Tung Y, Chi KH, Fountzilas G, Bourhis J, Pignon JP, Blanchard P. What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma?
An Individual Patient Data Network Meta-Analysis. J Clin Oncol. 2017 Feb 10;35(5):498–505.
Robbins KT Integrating radiologic criteria into the classification of cervical lymph node disease. Arch Otolaryngol Head Neck Surg.1999;125:385–7.
Rosenthal DI, Mohamed ASR, Garden AS, Morrison WH, ElNaggar AK, Kamal M, Weber RS, Fuller CD, Peters LJ. Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients With Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1002–11
Scala LM, Hu K, Urken ML, Jacobson AS, Persky MS, Tran TN, Smith ML, Schantz S, Harrison LB. Intraoperative
high-dose-rate radiotherapy in the management of locoregionally recurrent head and neck cancer. Head Neck. 2013 Apr;35(4):485–92.
Semrau R, Mueller RP, Stuetzer H, Staar S, Schroeder U, Guntinas-Lichius O, Kocher M, Eich HT, Dietz A, Flentje M, Rudat V, Volling P, Schroeder M, Eckel HE. Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1308–16.
Shah JP, Candela FC, Poddar AK. The patterns of cervical lymph node metastases from squamous carcinoma of the oral cavity. Cancer. 1990 Jul 1;66(1):109–13.
Sharma A, Mohanti BK, Thakar A, Bahadur S, Bhasker S. Concomitant chemoradiation versus radical radiotherapy in advanced squamous cell carcinoma of oropharynx and nasopharynx using weekly cisplatin: a phase II randomized trial. Ann Oncol. 2010 Nov;21(11): 2272–7.
Sher DJ, Balboni TA, Haddad RI, Norris CM Jr, Posner MR, Wirth LJ, Goguen LA, Annino D, Tishler RB. Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck. Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1405–11.
Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M, Flentje M, Eckel HE, Mueller RP. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced headand-neck cancer. Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1161–71.
TNM-Klassifikation maligner Tumore, 8. Auflage, 2017, Springer Verlag.
Tupchong L, Scott CB, Blitzer PH, Marcial VA, Lowry LD, Jacobs JR, Stetz J, Davis LW, Snow JB, Chandler R. Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73-03. Int J Radiat Oncol Biol Phys. 1991 Jan;20(1):21–8.
epartment of Veterans Affairs Laryngeal Cancer Study Group, Wolf GT, Fisher SG, Hong WK, Hillman R, Spaulding M, Laramore GE, Endicott JW, McClatchey K, Henderson WG. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991 Jun 13;324(24):1685–90.
Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL; EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007 Oct 25;357(17):1695–704.
Vokes EE, Agrawal N, Seiwert TY. HPV-Associated Head and Neck Cancer. J Natl Cancer Inst. 2015 Dec 9;107(12):djv344.
Kap. 4
Biermann, M., M. K. Pixberg, A. Schuck, A. Heinecke, W. Kopcke, K. W. Schmid, H. Dralle, N. Willich, and O. Schober. 2003. 'Multicenter study differentiated thyroid carcinoma (MSDS). Diminished acceptance of adjuvant external beam radiotherapy', Nuklearmedizin, 42:244–50.
Brierley, J., R. Tsang, T. Panzarella, and N. Bana. 2005. 'Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years', Clin Endocrinol (Oxf), 63:418–27.
Pezzi, T. A., A. S. R. Mohamed, T. Sheu, P. Blanchard, V. C. Sandulache, S. Y. Lai, M. E. Cabanillas, M. D. Williams, C. M. Pezzi, C. Lu, A. S. Garden, W. H. Morrison, D. I. Rosenthal, C. D. Fuller, and G. B. Gunn. 2017. 'Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base', Cancer, 123:1653–61.
Rao, S. N., M. Zafereo, R. Dadu, N. L. Busaidy, K. Hess, G. J. Cote, M. D. Williams, W. N. William, V. Sandulache, N. Gross, G. B. Gunn, C. Lu, R. Ferrarotto, S. Y. Lai, and M. E. Cabanillas. 2017. 'Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma', Thyroid, 27:672–81.
Sherman, E. J., S. H. Lim, A. L. Ho, R. A. Ghossein, M. G. Fury, A. R. Shaha, M. Rivera, O. Lin, S. Wolden, N. Y. Lee, and D. G. Pfister. 2011. 'Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review', Radiother Oncol, 101:425–30.
Simpson, W. J., T. Panzarella, J. S. Carruthers, M. K. Gospodarowicz, and S. B. Sutcliffe. 1988. 'Papillary and follicular thyroid cancer: impact of treatment in 1578 patients', Int J Radiat Oncol Biol Phys, 14:1063–75.
Tennvall, J., G. Lundell, A. Hallquist, P. Wahlberg, G. Wallin, and S. Tibblin. 1994. 'Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. The Swedish Anaplastic Thyroid Cancer Group', Cancer, 74:1348–54.
Tsang, R. W., M. K. Gospodarowicz, M. Pintilie, W. Wells, D. C. Hodgson, A. Sun, M. Crump, and B. J. Patterson. 2003. 'Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome', J Clin Oncol, 21:4157–64.
Tubiana, M., M. Schlumberger, P. Rougier, A. Laplanche, E. Benhamou, P. Gardet, B. Caillou, J. P. Travagli, and C. Parmentier. 1985. 'Long-term results and prognostic factors in patients with differentiated thyroid carcinoma', Cancer, 55:794–804.
Kap. 5
Amdal, C. D., A. B. Jacobsen, B. Sandstad, T. Warloe, and K. Bjordal. 2013. 'Palliative brachytherapy with or without primary stent placement in patients with oesophageal cancer, a randomised phase III trial', Radiother Oncol, 107:428–33.
Arnott, S. J., W. Duncan, M. Gignoux, H. S. Hansen, B. Launois, K. Nygaard, M. K. Parmar, A. Rousell, G. Spilopoulos, G. Stewart, J. F. Tierney, M. Wang, Z. Rhugang, and Group Oeosphageal Cancer Collaborative. 2005. 'Preoperative radiotherapy for esophageal carcinoma', Cochrane Database Syst Rev: CD001799.
Bang, Y. J., E. Van Cutsem, A. Feyereislova, H. C. Chung, L. Shen, A. Sawaki, F. Lordick, A. Ohtsu, Y. Omuro, T. Satoh, G. Aprile, E. Kulikov, J. Hill, M. Lehle, J. Ruschoff, Y. K. Kang, and G. A. Trial Investigators To. 2010. 'Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial', Lancet, 376:687–97.
Bedenne, L., P. Michel, O. Bouche, C. Milan, C. Mariette, T. Conroy, D. Pezet, B. Roullet, J. F. Seitz, J. P. Herr, B. Paillot, P. Arveux, F. Bonnetain, and C. Binquet. 2007. 'Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102', J Clin Oncol, 25:1160–8.
Conroy, T., M. P. Galais, J. L. Raoul, O. Bouche, S. GourgouBourgade, J. Y. Douillard, P. L. Etienne, V. Boige, I. Martel-Lafay, P. Michel, C. Llacer-Moscardo, E. Francois, G. Crehange, M. B. Abdelghani, B. Juzyna, L. Bedenne, A. Adenis, Digestive Federation Francophone de Cancerologie, and Unicancer-Gi Group. 2014. 'Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial', Lancet Oncol, 15:305–14.
Cooper, J. S., M. D. Guo, A. Herskovic, J. S. Macdonald, J. A. Martenson, Jr., M. Al-Sarraf, R. Byhardt, A. H. Russell, J. J. Beitler, S. Spencer, S. O. Asbell, M. V. Graham, and L. L. Leichman. 1999. 'Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group', JAMA, 281:1623–7.
Cunningham, D., W. H. Allum, S. P. Stenning, J. N. Thompson, C. J. Van de Velde, M. Nicolson, J. H. Scarffe, F. J. Lofts, S. J. Falk, T. J. Iveson, D. B. Smith, R. E. Langley, M. Verma, S. Weeden, Y. J. Chua, and Magic Trial Participants. 2006. 'Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer', N Engl J Med, 355:11–20.
Gaspar, L. E., C. Qian, W. I. Kocha, L. R. Coia, A. Herskovic, and M. Graham. 1997. 'A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92-07): preliminary toxicity report', Int J Radiat Oncol Biol Phys, 37:593–9.
Hulscher, J. B., J. G. Tijssen, H. Obertop, and J. J. van Lanschot. 2001. 'Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis', Ann Thorac Surg, 72:306–13.
Macdonald, J. S., S. R. Smalley, J. Benedetti, S. A. Hundahl, N. C. Estes, G. N. Stemmermann, D. G. Haller, J. A. Ajani,
L. L. Gunderson, J. M. Jessup, and J. A. Martenson. 2001. 'Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction', N Engl J Med, 345:725–30.
Matzinger, O., E. Gerber, Z. Bernstein, P. Maingon, K. Haustermans, J. F. Bosset, A. Gulyban, P. Poortmans, L. Collette, and A. Kuten. 2009. 'EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach', Radiother Oncol, 92:164–75.
Minsky, B. D., T. F. Pajak, R. J. Ginsberg, T. M. Pisansky, J. Martenson, R. Komaki, G. Okawara, S. A. Rosenthal, and D. P. Kelsen. 2002. 'INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standarddose radiation therapy', J Clin Oncol, 20:1167–74.
Nicolay, N. H., J. Rademacher, J. Oelmann-Avendano, J. Debus, P. E. Huber, and K. Lindel. 2016. 'High dose-rate endoluminal brachytherapy for primary and recurrent esophageal cancer : Experience from a large single-center cohort', Strahlenther Onkol, 192:458–66.
Penniment, M. G., P. B. De Ieso, J. A. Harvey, S. Stephens, H. J. Au, C. J. O'Callaghan, A. Kneebone, S. Y. Ngan, I. G. Ward, R. Roy, J. G. Smith, T. Nijjar, J. J. Biagi, L. A. Mulroy, R. Wong, and Trog Cctg Es group. 2018. 'Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01)', Lancet Gastroenterol Hepatol, 3:114–24.
Shapiro, J., J. J. B. van Lanschot, Mccm Hulshof, P. van Hagen, M. I. van Berge Henegouwen, B. P. L. Wijnhoven, H. W. M. van Laarhoven, G. A. P. Nieuwenhuijzen, G. A. P. Hospers, J. J. Bonenkamp, M. A. Cuesta, R. J. B. Blaisse, O. R. C. Busch, F. J. W. Ten Kate, G. M. Creemers, C. J. A. Punt, J. T. M. Plukker, H. M. W. Verheul, E. J. S. Bilgen, H. van Dekken, M. J. C. van der Sangen, T. Rozema, K. Biermann, J. C. Beukema, A. H. M. Piet, C. M. van Rij, J. G. Reinders, H. W. Tilanus, E. W. Steyerberg, A. van der Gaast, and Cross study group. 2015. 'Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial', Lancet Oncol, 16:1090–8.
Sjoquist, K. M., B. H. Burmeister, B. M. Smithers, J. R. Zalcberg, R. J. Simes, A. Barbour, V. Gebski, and Group Australasian Gastro-Intestinal Trials. 2011. 'Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated metaanalysis', Lancet Oncol, 12:681–92.
Stahl, M., M. Stuschke, N. Lehmann, H. J. Meyer, M. K. Walz, S. Seeber, B. Klump, W. Budach, R. Teichmann, M. Schmitt, G. Schmitt, C. Franke, and H. Wilke. 2005. 'Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus', J Clin Oncol, 23:2310–7.
Tepper, J., M. J. Krasna, D. Niedzwiecki, D. Hollis, C. E. Reed, R. Goldberg, K. Kiel, C. Willett, D. Sugarbaker, and
R. Mayer. 2008. 'Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781', J Clin Oncol, 26:1086–92.
van Hagen, P., M. C. Hulshof, J. J. van Lanschot, E. W. Steyerberg, M. I. van Berge Henegouwen, B. P. Wijnhoven, D. J. Richel, G. A. Nieuwenhuijzen, G. A. Hospers, J. J. Bonenkamp, M. A. Cuesta, R. J. Blaisse, O. R. Busch, F. J. ten Kate, G. J. Creemers, C. J. Punt, J. T. Plukker, H. M. Verheul, E. J. Spillenaar Bilgen, H. van Dekken, M. J. van der Sangen, T. Rozema, K. Biermann, J. C. Beukema, A. H. Piet, C. M. van Rij, J. G. Reinders, H. W. Tilanus, A. van der Gaast, and Cross Group. 2012. 'Preoperative chemoradiotherapy for esophageal or junctional cancer', N Engl J Med, 366:2074–84.
Wu, A. J., W. R. Bosch, D. T. Chang, T. S. Hong, S. K. Jabbour, L. R. Kleinberg, H. J. Mamon, C. R. Thomas, Jr., and K. A. Goodman. 2015. 'Expert Consensus Contouring Guidelines for Intensity Modulated Radiation Therapy in Esophageal and Gastroesophageal Junction Cancer', Int J Radiat Oncol Biol Phys, 92:911–20.
Yamamoto, M., T. Yamashita, T. Matsubara, T. Kitahara, K. Sekiguchi, M. Furukawa, A. Uki, M. Kobayashi, E. Tanaka, M. Ueda, and T. Nakajima. 1997. 'Reevaluation of postoperative radiotherapy for thoracic esophageal carcinoma', Int J Radiat Oncol Biol Phys, 37: 75–8.
Zhu, H. D., J. H. Guo, A. W. Mao, W. F. Lv, J. S. Ji, W. H. Wang, B. Lv, R. M. Yang, W. Wu, C. F. Ni, J. Min, G. Y. Zhu, L. Chen, M. L. Zhu, Z. Y. Dai, P. F. Liu, J. P. Gu, W. X. Ren, R. H. Shi, G. F. Xu, S. C. He, G. Deng, and G. J. Teng. 2014. 'Conventional stents versus stents loaded with (125)iodine seeds for the treatment of unresectable oesophageal cancer: a multicentre, randomised phase 3 trial', Lancet Oncol, 15:612–9.
Kap. 6
Bang, Y. J., E. Van Cutsem, A. Feyereislova, H. C. Chung, L. Shen, A. Sawaki, F. Lordick, A. Ohtsu, Y. Omuro, T. Satoh, G. Aprile, E. Kulikov, J. Hill, M. Lehle, J. Ruschoff, Y. K. Kang, and G. A. Trial Investigators To. 2010. 'Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial', Lancet, 376:687–97.
Cats, A., E. P. M. Jansen, N. C. T. van Grieken, K. Sikorska, P. Lind, M. Nordsmark, E. Meershoek-Klein Kranenbarg, H. Boot, A. K. Trip, H. A. M. Swellengrebel, H. W. M. van Laarhoven, H. Putter, J. W. van Sandick, M. I. van Berge Henegouwen, H. H. Hartgrink, H. van Tinteren, C. J. H. van de Velde, M. Verheij, and Critics investigators. 2018. 'Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial', Lancet Oncol.
Cunningham, D., W. H. Allum, S. P. Stenning, J. N. Thompson, C. J. Van de Velde, M. Nicolson, J. H. Scarffe, F. J. Lofts, S. J. Falk, T. J. Iveson, D. B. Smith, R. E. Langley, M. Verma, S. Weeden, Y. J. Chua, and Magic Trial Participants. 2006. 'Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer', N Engl J Med, 355:11–20.
Cuschieri, A., S. Weeden, J. Fielding, J. Bancewicz, J. Craven, V. Joypaul, M. Sydes, and P. Fayers. 1999. 'Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Cooperative Group', Br J Cancer, 79:1522–30.
Hartgrink, H. H., C. J. van de Velde, H. Putter, J. J. Bonenkamp, E. Klein Kranenbarg, I. Songun, K. Welvaart, J. H. van Krieken, S. Meijer, J. T. Plukker, P. J. van Elk, H. Obertop, D. J. Gouma, J. J. van Lanschot, C. W. Taat, P. W. de Graaf, M. F. von Meyenfeldt, H. Tilanus, and M. Sasako. 2004. 'Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial', J Clin Oncol, 22: 2069–77.
Kim, S., D. H. Lim, J. Lee, W. K. Kang, J. S. MacDonald, C. H. Park, S. H. Park, S. H. Lee, K. Kim, J. O. Park, W. S. Kim, C. W. Jung, Y. S. Park, Y. H. Im, T. S. Sohn, J. H. Noh, J. S. Heo, Y. I. Kim, C. K. Park, and K. Park. 2005. 'An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach', Int J Radiat Oncol Biol Phys, 63:1279–85.
Macdonald, J. S., S. R. Smalley, J. Benedetti, S. A. Hundahl, N. C. Estes, G. N. Stemmermann, D. G. Haller, J. A. Ajani, L. L. Gunderson, J. M. Jessup, and J. A. Martenson. 2001. 'Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction', N Engl J Med, 345:725–30.
Matzinger, O., E. Gerber, Z. Bernstein, P. Maingon, K. Haustermans, J. F. Bosset, A. Gulyban, P. Poortmans, L. Collette, and A. Kuten. 2009. 'EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach', Radiother Oncol, 92:164–75.
Ohtsu, A., M. A. Shah, E. Van Cutsem, S. Y. Rha, A. Sawaki, S. R. Park, H. Y. Lim, Y. Yamada, J. Wu, B. Langer, M. Starnawski, and Y. K. Kang. 2011. 'Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebocontrolled phase III study', J Clin Oncol, 29:3968–76.
Park, S. H., T. S. Sohn, J. Lee, D. H. Lim, M. E. Hong, K. M. Kim, I. Sohn, S. H. Jung, M. G. Choi, J. H. Lee, J. M. Bae, S. Kim, S. T. Kim, J. O. Park, Y. S. Park, H. Y. Lim, and W. K. Kang. 2015. 'Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses', J Clin Oncol, 33:3130–6.
Kap. 7
Appelt, A. L., J. Ploen, H. Harling, F. S. Jensen, L. H. Jensen, J. C. Jorgensen, J. Lindebjerg, S. R. Rafaelsen, and A. Jakobsen. 2015. 'High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study', Lancet Oncol, 16:919–27.
Bosset, J. F., G. Calais, L. Mineur, P. Maingon, S. StojanovicRundic, R. J. Bensadoun, E. Bardet, A. Beny, J. C. Ollier, M. Bolla, D. Marchal, J. L. Van Laethem, V. Klein, J. Giralt, P. Clavere, C. Glanzmann, P. Cellier, L. Collette, and Eortc Radiation Oncology Group. 2014. 'Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study', Lancet Oncol, 15:184–90.
Bujko, K., M. P. Nowacki, A. Nasierowska-Guttmejer, W. Michalski, M. Bebenek, and M. Kryj. 2006. 'Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer', Br J Surg, 93:1215–23.
Bujko, K., M. P. Nowacki, A. Nasierowska-Guttmejer, W. Michalski, M. Bebenek, M. Pudelko, M. Kryj, J. Oledzki, J. Szmeja, J. Sluszniak, K. Serkies, J. Kladny, M. Pamucka, and P. Kukolowicz. 2004. 'Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy', Radiother Oncol, 72:15–24.
Cunningham, D., Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, D. Bets, M. Mueser, A. Harstrick, C. Verslype, I. Chau, and E. Van Cutsem. 2004. 'Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer', N Engl J Med, 351:337–45. de Gramont, A., M. Buyse, J. C. Abrahantes, T. Burzykowski, E. Quinaux, A. Cervantes, A. Figer, G. Lledo, M. Flesch, L. Mineur, E. Carola, P. L. Etienne, F. Rivera, I. Chirivella, N. Perez-Staub, C. Louvet, T. Andre, I. Tabah-Fisch, and C. Tournigand. 2007. 'Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer', J Clin Oncol, 25:3224–9.
Erlandsson, J., T. Holm, D. Pettersson, A. Berglund, B. Cedermark, C. Radu, H. Johansson, M. Machado, F. Hjern, O. Hallbook, I. Syk, B. Glimelius, and A. Martling. 2017. 'Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, noninferiority trial', Lancet Oncol, 18:336–46.
Folkesson, J., H. Birgisson, L. Pahlman, B. Cedermark, B. Glimelius, and U. Gunnarsson. 2005. 'Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate', J Clin Oncol, 23:5644–50.
Giantonio, B. J., P. J. Catalano, N. J. Meropol, P. J. O'Dwyer, E. P. Mitchell, S. R. Alberts, M. A. Schwartz, A. B. Benson, 3rd, and E. Eastern Cooperative Oncology Group Study. 2007. 'Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated
e.8 Literatur zu Giordano/Wenz: Strahlentherapie kompakt, 3. Auflage
metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200', J Clin Oncol, 25:1539–44.
Gill, S., C. L. Loprinzi, D. J. Sargent, S. D. Thome, S. R. Alberts, D. G. Haller, J. Benedetti, G. Francini, L. E. Shepherd, J. Francois Seitz, R. Labianca, W. Chen, S. S. Cha, M. P. Heldebrant, and R. M. Goldberg. 2004. 'Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?', J Clin Oncol, 22:1797–806.
Gunderson, L. L., and H. Sosin. 1974. 'Areas of failure found at reoperation (second or symptomatic look) following "curative surgery" for adenocarcinoma of the rectum. Clinicopathologic correlation and implications for adjuvant therapy', Cancer, 34:1278–92.
Habr-Gama, A., R. O. Perez, W. Nadalin, S. C. Nahas, U. Ribeiro, Jr., E. Sousa A. H. Silva, Jr., F. G. Campos, D. R. Kiss, and J. Gama-Rodrigues. 2005. 'Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival', J Gastrointest Surg, 9:90–9; discussion 99–101.
Hofheinz, R. D., F. Wenz, S. Post, A. Matzdorff, S. Laechelt, J. T. Hartmann, L. Muller, H. Link, M. Moehler, E. Kettner, E. Fritz, U. Hieber, H. W. Lindemann, M. Grunewald, S. Kremers, C. Constantin, M. Hipp, G. Hartung, D. Gencer, P. Kienle, I. Burkholder, and A. Hochhaus. 2012. 'Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial', Lancet Oncol, 13:579–88.
Holm, T., T. Singnomklao, L. E. Rutqvist, and B. Cedermark. 1996. 'Adjuvant preoperative radiotherapy in patients with rectal carcinoma. Adverse effects during long term follow-up of two randomized trials', Cancer, 78:968–76.
Kabbinavar, F. F., J. Hambleton, R. D. Mass, H. I. Hurwitz, E. Bergsland, and S. Sarkar. 2005. 'Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/ leucovorin improves survival for patients with metastatic colorectal cancer', J Clin Oncol, 23:3706–12.
Kapiteijn, E., C. A. Marijnen, I. D. Nagtegaal, H. Putter, W. H. Steup, T. Wiggers, H. J. Rutten, L. Pahlman, B. Glimelius, J. H. van Krieken, J. W. Leer, C. J. van de Velde, and Group Dutch Colorectal Cancer. 2001. 'Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer', N Engl J Med, 345:638–46.
Lefevre, J. H., L. Mineur, S. Kotti, E. Rullier, P. Rouanet, C. de Chaisemartin, B. Meunier, J. Mehrdad, E. Cotte, J. Desrame, M. Karoui, S. Benoist, S. Kirzin, A. Berger, Y. Panis, G. Piessen, A. Saudemont, M. Prudhomme, F. Peschaud, A. Dubois, J. Loriau, J. J. Tuech, G. Meurette, R. Lupinacci, N. Goasgen, Y. Parc, T. Simon, and E. Tiret. 2016. 'Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6)', J Clin Oncol, 34:3773–80.
MacFarlane, J. K., R. D. Ryall, and R. J. Heald. 1993. 'Mesorectal excision for rectal cancer', Lancet, 341:457–60.
Martenson, J. A., Jr., C. G. Willett, D. J. Sargent, J. A. Mailliard, J. H. Donohue, L. L. Gunderson, C. R. Thomas, Jr., B. Fisher, A. B. Benson, 3rd, R. Myerson, and R. M. Goldberg. 2004. 'Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130', J Clin Oncol, 22:3277–83.
Mirnezami, R., G. J. Chang, P. Das, K. Chandrakumaran, P. Tekkis, A. Darzi, and A. H. Mirnezami. 2013. 'Intraoperative radiotherapy in colorectal cancer: systematic review and meta-analysis of techniques, long-term outcomes, and complications', Surg Oncol, 22:22–35.
O'Connell, M. J., L. H. Colangelo, R. W. Beart, N. J. Petrelli, C. J. Allegra, S. Sharif, H. C. Pitot, A. F. Shields, J. C. Landry, D. P. Ryan, D. S. Parda, M. Mohiuddin, A. Arora, L. S. Evans, N. Bahary, G. S. Soori, J. Eakle, J. M. Robertson, D. F. Moore, Jr., M. R. Mullane, B. T. Marchello, P. J. Ward, T. F. Wozniak, M. S. Roh, G. Yothers, and N. Wolmark. 2014. 'Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04', J Clin Oncol, 32:1927–34.
O'Connell, M. J., J. A. Martenson, H. S. Wieand, J. E. Krook, J. S. Macdonald, D. G. Haller, R. J. Mayer, L. L. Gunderson, and T. A. Rich. 1994. 'Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery', N Engl J Med, 331:502–7.
Pahlman, L., and B. Glimelius. 1990. 'Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial', Ann Surg, 211:187–95.
Peeters, K. C., C. A. Marijnen, I. D. Nagtegaal, E. K. Kranenbarg, H. Putter, T. Wiggers, H. Rutten, L. Pahlman, B. Glimelius, J. W. Leer, C. J. van de Velde, and Group Dutch Colorectal Cancer. 2007. 'The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma', Ann Surg, 246:693–701.
Quasar Collaborative, Group, R. Gray, J. Barnwell, C. McConkey, R. K. Hills, N. S. Williams, and D. J. Kerr. 2007. 'Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study', Lancet, 370:2020–9.
Rodel, C., U. Graeven, R. Fietkau, W. Hohenberger, T. Hothorn, D. Arnold, R. D. Hofheinz, M. Ghadimi, H. A. Wolff, M. Lang-Welzenbach, H. R. Raab, C. Wittekind, P. Strobel, L. Staib, M. Wilhelm, G. G. Grabenbauer, H. Hoffmanns, F. Lindemann, A. Schlenska-Lange, G. Folprecht, R. Sauer, T. Liersch, and Group German Rectal Cancer Study. 2015. 'Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/ AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial', Lancet Oncol, 16:979–89.
Rodel, C., T. Liersch, H. Becker, R. Fietkau, W. Hohenberger, T. Hothorn, U. Graeven, D. Arnold, M. Lang-Welzenbach, H. R. Raab, H. Sulberg, C. Wittekind, S. Potapov, L. Staib, C.
Hess, K. Weigang-Kohler, G. G. Grabenbauer, H. Hoffmanns, F. Lindemann, A. Schlenska-Lange, G. Folprecht, R. Sauer, and Group German Rectal Cancer Study. 2012. 'Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial', Lancet Oncol, 13:679–87.
Sauer, R., H. Becker, W. Hohenberger, C. Rodel, C. Wittekind, R. Fietkau, P. Martus, J. Tschmelitsch, E. Hager, C. F. Hess, J. H. Karstens, T. Liersch, H. Schmidberger, R. Raab, and Group German Rectal Cancer Study. 2004. 'Preoperative versus postoperative chemoradiotherapy for rectal cancer', N Engl J Med, 351:1731–40.
Sauer, R., T. Liersch, S. Merkel, R. Fietkau, W. Hohenberger, C. Hess, H. Becker, H. R. Raab, M. T. Villanueva, H. Witzigmann, C. Wittekind, T. Beissbarth, and C. Rodel. 2012. 'Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years', J Clin Oncol, 30:1926–33.
Sebag-Montefiore, D., R. J. Stephens, R. Steele, J. Monson, R. Grieve, S. Khanna, P. Quirke, J. Couture, C. de Metz, A. S. Myint, E. Bessell, G. Griffiths, L. C. Thompson, and M. Parmar. 2009. 'Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial', Lancet, 373:811–20.
Sobrero, A. F., J. Maurel, L. Fehrenbacher, W. Scheithauer, Y. A. Abubakr, M. P. Lutz, M. E. Vega-Villegas, C. Eng, E. U. Steinhauer, J. Prausova, H. J. Lenz, C. Borg, G. Middleton, H. Kroning, G. Luppi, O. Kisker, A. Zubel, C. Langer, J. Kopit, and H. A. Burris, 3rd. 2008. 'EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer', J Clin Oncol, 26:2311–9.
Swedish Rectal Cancer, Trial, B. Cedermark, M. Dahlberg, B. Glimelius, L. Pahlman, L. E. Rutqvist, and N. Wilking. 1997. 'Improved survival with preoperative radiotherapy in resectable rectal cancer', N Engl J Med, 336:980–7.
Tepper, J. E., M. J. O'Connell, D. Niedzwiecki, D. Hollis, C. Compton, A. B. Benson, 3rd, B. Cummings, L. Gunderson, J. S. Macdonald, and R. J. Mayer. 2001. 'Impact of number of nodes retrieved on outcome in patients with rectal cancer', J Clin Oncol, 19:157–63.
Twelves, C., A. Wong, M. P. Nowacki, M. Abt, H. Burris, 3rd, A. Carrato, J. Cassidy, A. Cervantes, J. Fagerberg, V. Georgoulias, F. Husseini, D. Jodrell, P. Koralewski, H. Kroning, J. Maroun, N. Marschner, J. McKendrick, M. Pawlicki, R. Rosso, J. Schuller, J. F. Seitz, B. Stabuc, J. Tujakowski, G. Van Hazel, J. Zaluski, and W. Scheithauer. 2005. 'Capecitabine as adjuvant treatment for stage III colon cancer', N Engl J Med, 352:2696–704.
Van Cutsem, E., C. H. Kohne, I. Lang, G. Folprecht, M. P. Nowacki, S. Cascinu, I. Shchepotin, J. Maurel, D. Cunningham, S. Tejpar, M. Schlichting, A. Zubel, I. Celik, P. Rougier, and F. Ciardiello. 2011. 'Cetuximab plus irinotecan,
fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status', J Clin Oncol, 29:2011–9.
van Gijn, W., C. A. Marijnen, I. D. Nagtegaal, E. M. Kranenbarg, H. Putter, T. Wiggers, H. J. Rutten, L. Pahlman, B. Glimelius, C. J. van de Velde, and Group Dutch Colorectal Cancer. 2011. 'Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12year follow-up of the multicentre, randomised controlled TME trial', Lancet Oncol, 12:575–82.
Vogelstein, B., E. R. Fearon, S. R. Hamilton, S. E. Kern, A. C. Preisinger, M. Leppert, Y. Nakamura, R. White, A. M. Smits, and J. L. Bos. 1988. 'Genetic alterations during colorectaltumor development', N Engl J Med, 319:525–32.
Wasan, H. S., P. Gibbs, N. K. Sharma, J. Taieb, V. Heinemann, J. Ricke, M. Peeters, M. Findlay, A. Weaver, J. Mills, C. Wilson, R. Adams, A. Francis, J. Moschandreas, P. S. Virdee, P. Dutton, S. Love, V. Gebski, A. Gray, Foxfire trial investigators, Sirflox trial investigators, F. OXFIRE-Global trial investigators, G. van Hazel, and R. A. Sharma. 2017. 'First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials', Lancet Oncol, 18:1159–71.
Kap. 8
AG HPV der Ständigen Impfkommission (STIKO): Wissenschaftliche Begründung für die Empfehlung der HPVImpfung für Jungen im Alter von 9 bis 14 Jahren; Epid Bull 2018;26:233–50
Ajani, JA et al.; Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial JAMA. 2008 Apr 23;299(16):1914–21
Bartenlink H et al.; Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups; JCO 1997 May;15(5):2040–9
Belkacemi Y et al.; Management of primary anal canal adenocarcinoma: a large retrospective study from the Rare Cancer Network; Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1274–83
Boman BM et al; Carcinoma of the anal canal a clinical and pathologc study of 188 cases; Cancer 1984 Jul 1;54(1):114–25
Bosset JF et al.; Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and Gastrointestinal Cooperative Groups; Eur J Cancer. 2003 Jan;39(1):45–51
Another random document with no related content on Scribd:
I knew well enough that my hair did not need cutting, and was about to say so when he butted in with:
“It’s Christmas to-morrow, you know, Mr. Henderson,” and while he was saying it he was pulling out the headrest. It was Christmas Eve, and I did not want to make him feel bad, so I let him go ahead. One thing I liked about him, he did not seem to be one of the talking kind; that is to say, he did not say much, but what he did say you felt that he meant. After he was through cutting my hair, he laid my head back, and, with those long swipes of his, laid the lather on all parts of me that showed above my collar. Then he commenced on me with his razor. He was long at this. He would lay his razor on above my cheekbone, and with one swipe would rake down over my cheek and land under the tip of my chin. I fairly held my breath. After he had given me a couple of swipes of that kind he stopped to wipe his razor.
“Look here,” said I; “what did you work at before you struck the barber trade?”
“Stock Yards,” said he, taking a swipe down the other side of my face with that infernal razor; “used to be a ripper,” he added. And before my mind’s eye came a long row of hogs strung up by the hind legs and my friend of the razor going down the line giving each one a slash down the middle. Again I held my breath, and, after a few more of those swiping cuts, I was washed off and jerked into an upright position.
“Singe?” I heard him say, and, before I could utter a protest a blaze of fire was dancing about my head. This was another case of hold your breath. Then I was thrown on my back again, and lengthy was massaging my face. He was handling it as though it was a piece of putty, and I wondered if I would know myself if I ever got a chance to look in the glass again. Then I was bounced into an upright position again, and I heard him say something about the danger of taking cold. The next I knew those long fingers were going through what was left of my hair, executing what he called an alcohol shampoo. There was nothing further he could do for me, but, as he presented me with my check, he slipped a bottle of hair tonic into my pocket.
“Greatest tonic on earth,” said he. “There are indications that your hair will begin to fall out in a few years, and you should be prepared.”
The check was two dollars and forty cents. I handed him three one dollar bills.
“Thanks!” said he, looking at the bills. “Sixty cents is the smallest tip I have had today, but it is all right, old man. Come in again.”
I clinched the bottle of hair tonic in one hand and a strong desire came to me to kill that barber on the spot. I took a step towards him. He had put the money away, had gotten hold of his razor with his right hand, and was stropping it on the palm of his left. A vision of those slashed hogs came before me, and I walked out, but if I ever meet that man separated from his razor, there is going to be trouble.
I am keeping a little book now and putting in it the things to be avoided. One of the first things down is to avoid a hotel barber shop on Christmas Eve. You can never forget that it is Christmas time. They commence telling you about it a week before Christmas, and don’t let up until a week after New Year’s.
When you first come into a hotel the boy shows you to your room, and after setting down your grip in the only place in the room where you would rather not have it, he fixes the windows. They most likely don’t need fixing, but he fixes them anyway. If they are shut, he opens them, and if they are open he shuts them. Then, if you don’t notice him, he stands on one foot awhile, then changes off and stands on the other. Then he coughs, and, if that doesn’t fetch you, he says:
“Anything more I can do for you?”
You say “No,” and he puts you down for a cheap guy and then goes down and tells the news to the rest of the bell hops.
The one who showed me up at this place wasn’t to be put off so easy. After he had worked all the old grafts he said:
“It’s going to be fine weather for Christmas.”
“All right,” said I. “If you will pull off a good sunshiny day, you can come to my room and get a half a dollar,” and then the little beggar asked me if I was going to be here Christmas. I got rid of this boy for the time being on a promise, but I knew that half would have to be paid if Christmas brought in a cyclone.
The elevator boy sprung a new one on me. He handed out a catchpenny Christmas box and said:
“Ain’t that a peach?”
“Sure,” said I, wondering what he would say next.
“Then put a stone in it,” said he. That cost me a quarter.
In the dining-room each waiter wished me a “Merry Christmas,” and then you would see his hand slide out toward you as though he could not help it. Every chambermaid on my floor swore that she had waited on me at some other hotel, but the boy at the coat room took the palm. He wiped off my boots with a cloth, helped me on with my coat and brushed it, then as I was walking away, said:
“Thank you, sah; thank you, very kindly.”
“What in H—— are you thanking me for; I didn’t give you anything.”
“No, sah; no, sah!” said he, hesitatingly; “I only thanked yo’ cause yo’ let me bresh yo’ off, sah.”
What a fellow needs is one of those change-holders that the street car conductors use, with a place for each kind of a coin. But he would need more than that. He would need a national bank to keep the thing supplied.
Yours, Jack.
“HOLDING PEOPLE’S HANDS THAT YOU HAVE NEVER BEEN INTRODUCED TO.”
Jack Henderson.
Swearing Off.
